This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
B-cell Small Lymphocytic Lymphoma Recurrent
and you are
between 18 and 99
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This was a Phase 1 multicenter study of bendamustine, rituximab and TRU-016 (BRT) in subjects with relapsed indolent B-cell lymphoma. This was a multiple-dose escalation study to determine the maximum-tolerated dose (MTD) of TRU-016 given in combination with rituximab and bendamustine and to determine a safe dosing regimen for the combination in up to 12 subjects with relapsed indolent lymphoma. The originally planned Phase 2 portion, an open-label, randomized study to evaluate the efficacy of BRT compared with BR, was not conducted.

Provided treatments

  • Drug: TRU-016
  • Drug: Bendamustine
  • Drug: Rituximab

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01317901. The sponsor of the trial is Aptevo Therapeutics and it is looking for 12 volunteers for the current phase.
Official trial title:
A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma